Amneal Pharmaceuticals (NYSE:AMRX) Shares Up 2%

Amneal Pharmaceuticals, Inc. (NYSE:AMRXGet Rating) rose 2% on Friday . The company traded as high as $2.13 and last traded at $2.09. Approximately 11,850 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 831,008 shares. The stock had previously closed at $2.05.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. The Goldman Sachs Group decreased their price target on Amneal Pharmaceuticals from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Monday, August 8th. StockNews.com cut Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 24th. Finally, TheStreet cut Amneal Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Friday, August 12th.

Amneal Pharmaceuticals Stock Up 1.5 %

The stock has a market cap of $631.33 million, a PE ratio of -2.38, a price-to-earnings-growth ratio of 0.14 and a beta of 1.29. The firm has a fifty day moving average of $2.46 and a 200 day moving average of $2.99. The company has a quick ratio of 1.03, a current ratio of 1.56 and a debt-to-equity ratio of 15.38.

Amneal Pharmaceuticals (NYSE:AMRXGet Rating) last posted its earnings results on Friday, August 5th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.03). The business had revenue of $559.40 million during the quarter, compared to analysts’ expectations of $534.44 million. Amneal Pharmaceuticals had a negative net margin of 6.29% and a positive return on equity of 56.26%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the company earned $0.23 EPS. On average, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. First Quadrant LLC CA acquired a new stake in shares of Amneal Pharmaceuticals in the 1st quarter valued at about $37,000. O Shaughnessy Asset Management LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Running Point Capital Advisors LLC acquired a new position in shares of Amneal Pharmaceuticals during the 1st quarter worth $42,000. Meeder Asset Management Inc. acquired a new position in shares of Amneal Pharmaceuticals during the 1st quarter worth $62,000. Finally, Sei Investments Co. grew its stake in Amneal Pharmaceuticals by 17.7% in the 1st quarter. Sei Investments Co. now owns 20,553 shares of the company’s stock valued at $62,000 after buying an additional 3,096 shares during the last quarter. Institutional investors and hedge funds own 32.93% of the company’s stock.

About Amneal Pharmaceuticals

(Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Read More

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.